Announcements Trials
Browse Landscape

Status

Active not recruiting 12Recruiting 10Terminated 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Afatinib 3niraparib 2lenvatinib 2ibrutinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Gefitinib 2Capecitabine 2Abiraterone Acetate 23-Iodobenzylguanidine 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1pomalidomide 1pirtobrutinib 1pertuzumab 1olaratumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × amivantamab × Clear all
NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Janssen Research & Development, LLC

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡